• 6 Mar, 2025
  Spago takes Tumorad-01 study to the next level – BioStock
• 19 Dec, 2024
  Spago’s CEO: We want to expand cancer treatment with effective radiopharmaceuticals – BioStock
• 7 May, 2024
  Spagos CEO: Advancing the Tumorad programme comes first – BioStock
• 27 Mar, 2024
  Spago Nanomedicals CEO: “huge commercial opportunities are unfolding – BioStock
• 9 Feb, 2024
  Springboard forspagos radionuclide cancer therapy – BioStock
• 15 Jan, 2024
  Spago’s phase I/IIa cancer trial progressing steadily – BioStock
• 20 Dec, 2023
  Positive data in Spago’s phase IIa endometriosis trial – BioStock
• 14 Dec, 2023
  First patient dosed in Spago’s phase I/IIa trial – BioStock
• 30 Oct, 2023
  Tumorads potential in transforming cancer care – BioStock
• 24 Oct, 2023
  Intervju med VD Mats Hansen – Börsvärlden